Innoviva, Inc.

Innoviva, Inc.

INVANYSE / NASDAQHealthcareSmall cap

$18.41$0.00 (0.0%)

Last close · Data as of Nov 20, 2026

Market cap
$1.6B
P/E
6.0x
EV / EBITDA
3.7x
Revenue
$411.3M
Net margin
65.9%
ROCE
10.3%

-13.0% over the last year

Innoviva, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-13.5%
3M
-12.3%
6M
-17.2%
1Y
-13.0%
5Y
+8.0%

52-week range

Day change $0.00 (0.0%) from $18.41 to $18.41 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in INVA, bought on each weekday since 2021.

News & filings

What Innoviva filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOther income of 159 million US dollars was 39% of revenue in fiscal 2025.

Strengths (1)

  • Return on equity rose from 3.4% to 23.1% between fiscal 2024 and fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.

Read moreShow less

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Sector
Healthcare
Shares outstanding
67.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.6B
P/E
6.0x
P/B
1.4x
EV / EBITDA
3.7x
EV / Sales
3.3x
P/S
4.0x
52-week high
$24.24
52-week low
$18.30

Profitability

Operating margin
39.8%
Net margin
65.9%
EBITDA margin
89.9%
ROE
23.1%
ROCE
10.3%
ROA
16.6%
Asset turnover
0.25

Growth

Revenue
$411.3M
Revenue growth, 1Y
14.7%
Revenue CAGR, 3Y
7.5%
Net profit growth, 1Y
1059.2%
Free cash flow
$186.4M

Solvency

Current ratio
14.64
Debt / Equity
0.23
Debt / Assets
0.16
CFO / Net profit
0.73
Cash / Market cap
33.7%

Where the revenue went

Of every $100 of FY2025 revenue, $66 was left as net income.

Innoviva, Inc. income statement flow, FY2025
Innoviva, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$77.4M
RevenueGross profit$333.9M
Gross profitResearch and development$30.6M
Gross profitSelling, general and administrative$113.3M
Gross profitOther operating expenses$26.3M
Gross profitOperating income$163.7M
Operating incomePretax income$163.7M
Interest and other incomePretax income$163.1M
Pretax incomeTax and other$55.7M
Pretax incomeNet income$271.2M

Revenue and net profit

Revenue grew 14.7% in FY2025; net profit is the dashed line.

Innoviva, Inc. revenue and net profit by fiscal year
Innoviva, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$331.3M$213.9M
FY2023$310.5M$179.7M
FY2024$358.7M$23.4M
FY2025$411.3M$271.2M

Cash flows

FY2025: $196.9M from operations, $186.4M free after investment (dashed).

Innoviva, Inc. operating and free cash flow by fiscal year
Innoviva, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$201.7M$201.7M
FY2023$141.1M$140.7M
FY2024$188.7M$184.4M
FY2025$196.9M$186.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$411.3M+14.7%1Y
EBITDA
$369.8M+332.6%1Y
Net profit
$271.2M+1,059.2%1Y
Cash from operations
$196.9M+4.4%1Y
Free cash flow
$186.4M+1.1%1Y
Revenue CAGR, 3Y
7.5%
Net profit CAGR, 3Y
8.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$411.3M$369.8M$271.2M$186.4M23.1%+14.7%+1059.2%

Monthly returns

Month-by-month returns of INVA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.6B
Liabilities$462.3M
Equity$1.2B
Paid-in capital$902.7M
Retained earnings$269.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; INVA highlighted.

P/E against peers

INVA trades at 6.0x earnings against a peer median of -13.5x.

  1. Innoviva, Inc. (this company)6.0x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Palvella Therapeutics, Inc., Capricor Therapeutics, Inc., Tyra Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Innoviva, Inc.INVAthis company$1.6B6.0x1.4x23.1%3.7x
Novavax, Inc.NVAX$1.7B3.8x-13.1x-344.7%3.4x
Addus HomeCare CorporationADUS$1.7B17.5x1.5x8.8%11.2x
GeneDx Holdings Corp.WGS$1.7B-79.5x5.4x-6.8%138.2x
Palvella Therapeutics, Inc.PVLA$1.6B-39.5x58.9x-149.1%-44.3x
Fortrea Holdings Inc.FTRE$1.6B—2.9x-175.0%—
Capricor Therapeutics, Inc.CAPR$1.6B-15.4x5.3x-34.4%-13.4x
Tyra Biosciences, Inc.TYRA$1.6B-13.5x6.2x-46.3%-11.7x
Syndax Pharmaceuticals, Inc.SNDX$1.6B-5.6x24.7x-441.6%-7.2x
Peer median—-13.5x5.4x-97.7%-7.2x

Year-to-date ROI

INVA since 1 January, against earlier years.

Historical volatility

INVA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Innoviva, Inc. operating margin by fiscal year
Innoviva, Inc. operating margin by fiscal year
DateOperating margin
FY202262.5%
FY202336.7%
FY202446.5%
FY202539.8%
LineFY2025
Cost of revenueCost Of Revenue$77.4M
Gross profitGross Profit$333.9M
Operating expensesOperating Expense$170.2M
Research and developmentResearch And Development$30.6M
Depreciation and amortisationDepreciation And Amortization In Income Statement$26.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$26.3M
Amortization$26.3M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$26.3M
Total expensesTotal Expenses$247.6M
Pretax incomePretax Income$326.9M

Learn while you research

Academy chapters picked for Innoviva, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 6.0 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →